Extracellular Vesicle-Enclosed Oxidative Stress- and Inflammation-Related microRNAs as Potential Biomarkers of Vitamin D Responsivity: A Pilot Study on Inflammatory Bowel Disease Patients with or without COVID-19.

COVID-19 Crohn’s disease SARS-CoV-2 bioinformatics biomarkers extracellular vesicles inflammation inflammatory bowel diseases oxidative stress ulcerative colitis vitamin D

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
28 Aug 2024
Historique:
received: 03 07 2024
revised: 15 08 2024
accepted: 25 08 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

The relationship between serum 25-hydroxyvitamin D (25(OH)D) levels, genomic response to vitamin D (Vit.D), and positivity to SARS-CoV-2 remains understudied. In this pilot study, during the follow-up of patients with Inflammatory Bowel Disease (IBD) and COVID-19, we investigated this issue by analyzing the molecular contents of serum extracellular vesicles (EVs) from six groups of IBD patients (n = 32), classified according to anti-SARS-CoV-2 status, 25(OH)D level, and Vit.D supplementation, by small RNA-seq. This analysis revealed differentially expressed miRNAs, PIWI-RNA, transfer RNA, small nucleolar RNAs, and protein-coding RNAs in the EVs obtained from these cohorts of IBD patients. Experimental validation evidenced a statistically significant increase in miR30d-5p, miR150-5p, Let-7f-5p, and Let-7a-5p in the anti-SARS-CoV-2-positive and low 25(OH)D and Vit.D supplemented groups with respect to the non-Vit.D supplemented group, indicating their responsiveness to Vit.D treatment. Bioinformatics analysis highlighted the regulation of these validated miRNAs by oxidative stress and inflammation, hallmarks of IBD and COVID-19. Our study reports an unprecedented panel of circulating EV-enclosed inflammation- and oxidative stress-related miRNAs, the potentiality of which, as biomarkers for Vit.D responsivity in IBD patients, needs to be explored in future studies on larger cohorts in order to allow clinicians to optimize current treatment strategies upon viral infection.

Identifiants

pubmed: 39334706
pii: antiox13091047
doi: 10.3390/antiox13091047
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Area Science Park and Piattaforma di Genomica del Sistema ARGO with the support of Regione Autonoma Friuli Venezia Giulia, Ministry of University and Research and Ministry of Economic development
ID : FAST TRACK COVID 19
Organisme : Ricerca Locale - Linea A - Department of Veterinary Sciences, University of Torino
ID : Ricerca Locale

Auteurs

Giorgia Ammirata (G)

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre "Guido Tarone", University of Turin, 10126 Turin, Italy.

Maddalena Arigoni (M)

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre "Guido Tarone", University of Turin, 10126 Turin, Italy.

Danilo Licastro (D)

AREA Science Park, Padriciano, 34149 Trieste, Italy.

Gian Paolo Caviglia (GP)

Gastroenterology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Michela Disabato (M)

Gastroenterology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Ghania Zubair (G)

Department of Mathematics "Giuseppe Peano", University of Turin, 10126 Turin, Italy.

Cristina Bezzio (C)

IBD Centre, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.

Simone Saibeni (S)

Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Milan, Italy.

Amedeo De Nicolò (A)

Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, 10149 Turin, Italy.

Jessica Cusato (J)

Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, 10149 Turin, Italy.

Alice Palermiti (A)

Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, 10149 Turin, Italy.

Alessandra Manca (A)

Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, 10149 Turin, Italy.

Emanuela Tolosano (E)

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre "Guido Tarone", University of Turin, 10126 Turin, Italy.

Stefano Cozzini (S)

AREA Science Park, Padriciano, 34149 Trieste, Italy.

Marcello Mancini (M)

Institute for Biostructure and Bioimaging, CNR, Via T. De Amicis 95, 80145 Naples, Italy.

Fiorella Altruda (F)

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre "Guido Tarone", University of Turin, 10126 Turin, Italy.

Antonio D'Avolio (A)

Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, 10149 Turin, Italy.

Davide Giuseppe Ribaldone (DG)

Gastroenterology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Ugo Ala (U)

Department of Veterinary Sciences, University of Turin, Grugliasco, 10095 Turin, Italy.

Sharmila Fagoonee (S)

Institute for Biostructure and Bioimaging, CNR, Molecular Biotechnology Centre "Guido Tarone", 10126 Turin, Italy.

Classifications MeSH